1
|
Altieri DC and Marchisio PC: Survivin
apoptosis: an interloper between cell death and cell proliferation
in cancer. Lab Invest. 79:1327–1333. 1999.PubMed/NCBI
|
2
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Choi J and Chang H: The expression of MAGE
and SSX, and correlation of COX2, VEGF, and survivin in colorectal
cancer. Anticancer Res. 32:559–564. 2012.PubMed/NCBI
|
4
|
Suzuki A, Hayashida M, Ito T, Kawano H,
Nakano T, Miura M, Akahane K and Shiraki K: Survivin initiates cell
cycle entry by the competitive interaction with Cdk4/p16(INK4a) and
Cdk2/cyclin E complex activation. Oncogene. 19:3225–3234. 2000.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Takahashi Y, Kitadai Y, Bucana CD, Cleary
KR and Ellis LM: Expression of vascular endothelial growth factor
and its receptor, KDR, correlates with vascularity, metastasis, and
proliferation of human colon cancer. Cancer Res. 55:3964–3968.
1995.PubMed/NCBI
|
6
|
Toi M, Inada K, Suzuki H and Tominaga T:
Tumour angiogenesis in breast cancer: its importance as a
prognostic indicator and the association with vascular endothelial
growth factor expression. Breast Cancer Res Treat. 36:193–204.
1995. View Article : Google Scholar : PubMed/NCBI
|
7
|
Guenova ML, Balatzenko GN, Nikolova VR,
Spassov BV and Konstantinov SM: An anti-apoptotic pattern
correlates with multidrug resistance in acute myeloid leukemia
patients: a comparative study of active caspase-3, cleaved PARPs,
Bcl-2, Survivin and MDR1 gene. Hematology. 15:135–143. 2010.
View Article : Google Scholar
|
8
|
Redaelli A, Laskin BL, Stephens JM,
Botteman MF and Pashos CL: A systematic literature review of the
clinical and epidemiological burden of acute lymphoblastic
leukaemia (ALL). Eur J Cancer Care (Engl). 14:53–62. 2005.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Pui CH, Campana D, Pei D, et al: Treating
childhood acute lymphoblastic leukemia without cranial irradiation.
N Engl J Med. 360:2730–2741. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Li F, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by survivin. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Altieri DC: Survivin in apoptosis control
and cell cycle regulation in cancer. Prog Cell Cycle Res.
5:447–452. 2003.PubMed/NCBI
|
12
|
Esh AM, Atfy M, Azizi NA, El Naggar MM,
Khalil EE and Sherief L: Prognostic significance of survivin in
pediatric acute lymphoblastic leukemia. Indian J Hematol Blood
Transfus. 27:18–25. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Morrison DJ, Hogan LE, Condos G, et al:
Endogenous knockdown of survivin improves chemotherapeutic response
in ALL models. Leukemia. 26:271–279. 2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ma W, Yao X, Tang F, et al: Regulation of
pathway of survivin-NF-κB of leukemia HL60/adr cells by Jiedu Huayu
Fang. J Beijing Univ Tradit Chin Med. 35:25–28. 2012.(In
Chinese).
|
15
|
Demacq C, Vasconcellos VB, Izidoro-Toledo
TC, et al: Vascular endothelial growth factor (VEGF) and
endothelial nitric oxide synthase (NOS3) polymorphisms are
associated with high relapse risk in childhood acute lymphoblastic
leukemia (ALL). Clin Chim Acta. 411:1335–1340. 2010. View Article : Google Scholar : PubMed/NCBI
|